Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207275 | 0.85 | KDM4E (0.48) | TSHRLMNAMEN1CYP2C9KMT2A | |
| Diphenylmethanol SCHEMBL11564700 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL41571 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL6434457 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL10868602 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL8164003 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| SCHEMBL8671295 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL9324200 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL15641329 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TSHRCA12CA1 | |
| Diphenylmethanol SCHEMBL29571414 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1TSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| CN-103508838-B | Preparation method of diphenylmethane compounds | DALIAN CHEMICAL PHYSICS INST | 2015-01-14 | — | — | CN | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-2121609-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| WO-2008091818-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-4791126-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-13 | — | — | US | claimed |
| EP-0133103-B1 | BENZYL-PHENYL OSIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1987-11-11 | — | — | EP | claimed |
| US-4598068-A | Benzylphenyl osides, method of preparation and use therefor | Societe de Recheres Industrielles (FR) | 1986-07-01 | — | — | US | claimed |
| EP-0047109-B1 | RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | claimed |
| US-4463004-A | ANALGESICS | DELALANDE S.A. (FR) | 1984-07-31 | — | — | US | claimed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | claimed |
| JP-56167766-A | — | — | None | — | — | JP | disclosed |
| CN-110372777-A | A kind of liquid-phase synthesis process carrying out target polypeptides based on phosphorous small molecule carrier PSS | 西北工业大学 | 2019-10-25 | — | — | CN | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| CN-105315120-A | Method for benzene and methanol alkylation reaction | CHINA PETROLEUM & CHEMICAL | 2016-02-10 | — | — | CN | disclosed |
| CN-105272797-A | Benzene and methanol alkylation reaction method | CHINA PETROLEUM & CHEMICAL | 2016-01-27 | — | — | CN | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2845849-A1 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2021323-B1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8633310-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| EP-2635559-A2 | NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8530471-B2 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1829854-B1 | PROCESS FOR PRODUCING AROMATIC CARBONATE | ASAHI KASEI CHEMICALS CORP (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8440819-B2 | Therapeutic substituted beta-lactams | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-101522669-B | Therapeutic lactams | ALLERGAN INC | 2013-01-16 | — | — | CN | disclosed |
| EP-2331521-B1 | COMPOUNDS FOR GROWING HAIR | ALLERGAN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2019820-B1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | ALLERGAN INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8278347-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8263593-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8198318-B2 | Therapeutic amides | ALLERGEN, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8124648-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8093282-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110263692-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8003678-B2 | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101084181-B | Preparation method of aromatic polycarbonate | ASAHI CHEMICAL IND (JP) | 2011-07-27 | — | — | CN | disclosed |
| US-7985767-B2 | Glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; carboxy-functional amides or sulfonamide and carboxy bioisosteres thereof; 5-(-3-(N-(4-(1-hydroxyhexyl)phenyl)acetamido)butyl)thiophene-2-carboxylic acid for example | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110152255-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2011-06-23 | — | — | US | disclosed |
| US-7964596-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964599-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964634-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2331521-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7960379-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| CN-102089285-A | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN INC | 2011-06-08 | — | — | CN | disclosed |
| CN-102089295-A | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN INC | 2011-06-08 | — | — | CN | disclosed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| CN-102083807-A | Therapeutic compounds | ALLERGAN INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110112166-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2027082-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2303836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2300439-A1 | THERAPEUTIC SUBSTITUTED HYDANTOINS, AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2297084-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2049467-B1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7897629-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2285796-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285790-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285775-A1 | THERAPEUTIC LACTAMS | Allergan, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2285782-A2 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | Allergan, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2257548-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7795287-B2 | Therapeutic substituted hydantoins and related compounds | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-7786150-B2 | Therapeutic compounds | OLD DAVID W | 2010-08-31 | — | — | US | disclosed |
| US-7786117-B2 | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7713967-B2 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713968-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7700627-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100093809-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010019536-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7659295-B2 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090318449-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-7629485-B2 | Process for producing aromatic carbonate | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-12-08 | — | — | US | disclosed |
| WO-2009142969-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090281104-A1 | Therapeutic Compounds | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137413-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137345-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137339-A2 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137343-A1 | THERAPEUTIC SUBSTITUTED HYDANTOINS, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137544-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281101-A1 | THERAPEUTIC SUBSTITUTED HYDANTOINS, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281102-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281171-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090275646-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131977-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009117378-A2 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009114744-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114467-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114307-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233931-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090233921-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090227636-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227635-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| CN-101522669-A | Therapeutic lactams | ALLERGAN INC (US) | 2009-09-02 | — | — | CN | disclosed |
| WO-2009105440-A1 | BETA-LACTAMS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105438-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209538-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7576112-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7557095-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | OLD DAVID W | 2009-06-25 | — | — | US | disclosed |
| US-7550448-B2 | Glaucoma; 3-halopyrrolidine compounds; prostaglandin EP2 receptor modulators | ALLERGAN, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7547727-B2 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-2066660-A2 | THERAPEUTIC LACTAMS | Allergan, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2057128-A2 | THERAPEUTIC SUBSTITUTED HYDANTOINS AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2054409-A2 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2049495-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | Allergan, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049467-A2 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090099249-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-2044041-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | Allergan, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-2029518-A2 | CYCLOPENTANE-DERIVATIVES AND THEIR USE AS OCULAR HYPOTENSIVE AGENTS | Allergan, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7498447-B2 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted pyrrolidine compounds | ALLERGAN, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-2027081-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | Allergan, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027082-A1 | 12-ARYL OR HETEROARYL PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7491844-B2 | Therapeutic cyclopentane derivatives | ALLERGAN, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-2021322-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | Allergan, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021323-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | Allergan, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2019820-A1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | Allergan, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7482475-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7476755-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| WO-2007131012-A9 | 12-ARYL OR HETEROARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7468360-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7439372-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080177099-A1 | Process for Producing Aromatic Carbonate | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| WO-2008028032-A2 | THERAPEUTIC SUBSTITUTED HYDANTOINS AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | ALLERGAN, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008024765-A2 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008021975-A2 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008021933-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021804-A2 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080033023-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted pyrrolidine compounds | OLD DAVID W | 2008-02-07 | — | — | US | disclosed |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2007140197-A1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140136-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| CN-101084181-A | Asahi chemical corp (jp) | ASAHI CHEMICAL CORP (JP) | 2007-12-05 | — | — | CN | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| WO-2007134085-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007130890-A2 | CYCLOPENTANE-DERIVATIVES AND THEIR USE AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130902-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007131012-A1 | 12-ARYL OR HETEROARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1829854-A1 | PROCESS FOR PRODUCING AROMATIC CARBONATE | Asahi Kasei Chemicals Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-1090017-B1 | NOVEL COMPOUNDS DERIVED FROM ALPHA-D-XYLOSE, PREPARATION METHOD AND THERAPEUTIC USE | FOURNIER IND & SANTE (FR) | 2002-10-30 | — | — | EP | disclosed |
| US-6291433-B1 | Derivatives of α-D-Thioxyloside and their use against atheroma | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-09-18 | — | — | US | disclosed |
| EP-1090017-A1 | NOVEL COMPOUNDS DERIVED FROM $g(a)-D-XYLOSE, PREPARATION METHOD AND THERAPEUTIC USE | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-04-11 | — | — | EP | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999067261-A1 | NOVEL COMPOUNDS DERIVED FROM α-D-XYLOSE, PREPARATION METHOD AND THERAPEUTIC USE | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
| CN-1027268-C | Process for preparing benzopyrone-beta-D-thioxylosides | FOURNIER IND & SANTE (FR) | 1995-01-04 | — | — | CN | disclosed |
| CN-1024801-C | Process for preparing beta-D-phenyl-thioxylosides and their use | FOURNIER INNOVATION SYNERGIE (FR) | 1994-06-01 | — | — | CN | disclosed |
| CN-1020614-C | METHOD FOR PREPARING BETA-D-PHENYL-THIOXYLOSIDE | FOURNIER INNOVATION SYNERGIE (FR) | 1993-05-12 | — | — | CN | disclosed |
| CN-1050544-A | Novel benzopyrone-β-D-sulfo-xyloside, their preparation method and the application in treatment thereof | FOURNIER IND & SANTE (FR) | 1991-04-10 | — | — | CN | disclosed |
| EP-0367671-A2 | Novel beta-D-phenylthioxylosides, their method of preparation and their use as pharmaceuticals | FOURNIER INDUSTRIE ET SANTE (FR) | 1990-05-09 | — | — | EP | disclosed |
| CN-1041948-A | New this glucosides of B-D-phenyl sulfo-and preparation method thereof and therepic use | FOURNIER INNOVATION SYNERGIE (FR) | 1990-05-09 | — | — | CN | disclosed |
| US-4831045-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| CN-88102569-A | Novel beta-D-phenyl-thioxylosides, process for their preparation and their use in medical treatment | — | 1988-12-14 | — | — | CN | disclosed |
| US-4791126-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4598068-A | Benzylphenyl osides, method of preparation and use therefor | Societe de Recheres Industrielles (FR) | 1986-07-01 | — | — | US | disclosed |
| US-4598068-A | Benzylphenyl osides, method of preparation and use therefor | Societe de Recheres Industrielles (FR) | 1986-07-01 | — | — | US | disclosed |
| EP-0047109-B1 | RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4464382-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4463004-A | ANALGESICS | DELALANDE S.A. (FR) | 1984-07-31 | — | — | US | disclosed |
| US-4463004-A | ANALGESICS | DELALANDE S.A. (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0051023-B1 | DERIVATIVES OF THE BENZOYL AND ALPHA HYDROXYBENZYL-PHENYL OSIDES FAMILY, METHOD FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1984-05-30 | — | — | EP | disclosed |
| EP-0047109-A1 | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
| JP-S56167766-A | HIGHLY THICK COAT-TYPE PAINT | AISIN CHEM CO LTD | 1981-12-23 | — | — | JP | disclosed |
| JP-S56167766-A | HIGHLY THICK COAT-TYPE PAINT | AISIN CHEM CO LTD | 1981-12-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281171-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ABAT, ABCB1, TPMT | SMN1; SMN2 3707/4885L3MBTL1 3536/4885TSHR 1819/4885 |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | SMN1; SMN2 4867/4885L3MBTL1 4883/4885TSHR 745/4885 |
| US-20110263692-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | SMN1; SMN2 1812/4885L3MBTL1 4299/4885TSHR 4382/4885 |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | GOT2, ACER2, GOT1 | SMN1; SMN2 2438/4885L3MBTL1 4556/4885TSHR 2257/4885 |
| US-20090247594-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | SMN1; SMN2 1412/4885L3MBTL1 3886/4885TSHR 3467/4885 |
| US-20090227635-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, ABCB11, ACER2 | SMN1; SMN2 1318/4885L3MBTL1 3590/4885TSHR 3537/4885 |
| US-20090209538-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | DAO, TUBB2A, TOP1 | SMN1; SMN2 1722/4885L3MBTL1 3773/4885TSHR 3998/4885 |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | SMN1; SMN2 3307/4885L3MBTL1 4794/4885TSHR 3963/4885 |
| US-20110152255-A1 | THERAPEUTIC COMPOUNDS | SLC10A2, CYP11B1, CYP11B2 | SMN1; SMN2 3127/4885L3MBTL1 4754/4885TSHR 4760/4885 |
| US-20090099249-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | SMN1; SMN2 3815/4885L3MBTL1 4407/4885TSHR 4505/4885 |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | SMN1; SMN2 3815/4885L3MBTL1 4407/4885TSHR 4505/4885 |
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | SMN1; SMN2 2020/4885L3MBTL1 4740/4885TSHR 1819/4885 |
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | SMN1; SMN2 2157/4885L3MBTL1 3313/4885TSHR 4344/4885 |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | SI, GGPS1, B3GAT3 | SMN1; SMN2 1607/4885L3MBTL1 3319/4885TSHR 4249/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | SMN1; SMN2 2131/4885L3MBTL1 4403/4885TSHR 2420/4885 |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | SMN1; SMN2 84/4885L3MBTL1 3308/4885TSHR 105/4885 |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | SMN1; SMN2 2356/4885L3MBTL1 1788/4885TSHR 3315/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | SMN1; SMN2 2991/4885L3MBTL1 3994/4885TSHR 2567/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | SMN1; SMN2 3815/4885L3MBTL1 4407/4885TSHR 4505/4885 |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | SMN1; SMN2 2157/4885L3MBTL1 3313/4885TSHR 4344/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | SMN1; SMN2 1920/4885L3MBTL1 3867/4885TSHR 3918/4885 |
| US-20090281101-A1 | THERAPEUTIC SUBSTITUTED HYDANTOINS, AND RELATED COMPOUNDS | AADAC, ABCG2, SLC10A1 | SMN1; SMN2 3324/4885L3MBTL1 1424/4885TSHR 3201/4885 |
| US-20090227636-A1 | THERAPEUTIC COMPOUNDS | ACER2, ASAH2, SLC10A1 | SMN1; SMN2 1362/4885L3MBTL1 4085/4885TSHR 3559/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1149/4885L3MBTL1 2781/4885TSHR 4714/4885 |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | SMN1; SMN2 1812/4885L3MBTL1 4299/4885TSHR 4382/4885 |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ACER2, SLC10A1, ASAH2 | SMN1; SMN2 2274/4885L3MBTL1 2999/4885TSHR 2915/4885 |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | SMN1; SMN2 3398/4885L3MBTL1 1105/4885TSHR 4066/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | SMN1; SMN2 2020/4885L3MBTL1 4740/4885TSHR 1819/4885 |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1306/4885L3MBTL1 2793/4885TSHR 4746/4885 |
| US-20100093809-A1 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | THPO, MT-ND4L, ABAT | SMN1; SMN2 3813/4885L3MBTL1 4466/4885TSHR 1896/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | SMN1; SMN2 4882/4885L3MBTL1 4593/4885TSHR 562/4885 |
| US-20090281102-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT1, NAT1, TK1 | SMN1; SMN2 1190/4885L3MBTL1 3463/4885TSHR 3063/4885 |
| US-20090281104-A1 | Therapeutic Compounds | SLC10A1, ABCB11, GUSB | SMN1; SMN2 1306/4885L3MBTL1 3358/4885TSHR 3776/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1149/4885L3MBTL1 2781/4885TSHR 4714/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | SMN1; SMN2 1812/4885L3MBTL1 4299/4885TSHR 4382/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | SMN1; SMN2 4884/4885L3MBTL1 4531/4885TSHR 387/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | SMN1; SMN2 1412/4885L3MBTL1 3886/4885TSHR 3467/4885 |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1149/4885L3MBTL1 2781/4885TSHR 4714/4885 |
| US-20080033023-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted pyrrolidine compounds | PTGER2, PTGS2, PTGIS | SMN1; SMN2 4750/4885L3MBTL1 4868/4885TSHR 1927/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | SMN1; SMN2 2991/4885L3MBTL1 3994/4885TSHR 2567/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1149/4885L3MBTL1 2781/4885TSHR 4714/4885 |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, UGT2B7, GBA1 | SMN1; SMN2 2680/4885L3MBTL1 3055/4885TSHR 2289/4885 |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ABCB1, CYP11B2, SLC10A1 | SMN1; SMN2 2885/4885L3MBTL1 4690/4885TSHR 3551/4885 |
| US-20090233931-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, ABCB11, ACER2 | SMN1; SMN2 1268/4885L3MBTL1 2816/4885TSHR 4242/4885 |
| US-20090233921-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PDE3A, CYP11B2, PDE7A | SMN1; SMN2 2718/4885L3MBTL1 4576/4885TSHR 3585/4885 |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | VIP, SHH, GLI1 | SMN1; SMN2 4385/4885L3MBTL1 4695/4885TSHR 1481/4885 |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | SMN1; SMN2 1149/4885L3MBTL1 2781/4885TSHR 4714/4885 |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | PIGO, GARS1, CLPP | SMN1; SMN2 3289/4885L3MBTL1 3603/4885TSHR 4545/4885 |
| US-20090318449-A1 | THERAPEUTIC LACTAMS | ABCB11, TOP1, SLC10A2 | SMN1; SMN2 1173/4885L3MBTL1 3299/4885TSHR 4739/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | SMN1; SMN2 2177/4885L3MBTL1 4172/4885TSHR 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.